중합효소 연쇄반응(PCR) 시장(2026-2032년)
감염병 부담 증가, 개인 맞춤 의학 혁명, 유전체학 연구 붐 및 의료 분야의 암 진단 및 모니터링. 따라서 전염병 부담 증가, 개인 맞춤 의학 혁명, 유전체학 연구 붐 및 암 진단, 의료 부문 모니터링의 증가로 인해 2024년 109억 5,000만 달러를 돌파하고 2032년까지 173억 2,000만 달러 규모에 이르는 성장세를 보일 것입니다.
법의학의 발전은 극소량의 범죄 현장 샘플에서 DNA 프로파일링을 수행하기 때문에 개발도상국 및 소규모 산업에서 점점 더 널리 보급되고 있습니다. 따라서 법의학 발전은 신흥국에서 인기를 얻고 있으며, 2026-2032년 연평균 복합 성장률(CAGR) 6.50% 시장 성장을 가능하게 하고 있습니다.
중합효소 연쇄반응(PCR) 시장 : 정의/개요
중합효소 연쇄반응(PCR)은 극소량의 DNA 샘플에서 수백만 개의 복제본을 생성할 수 있는 획기적인 기술로 여겨지고 있습니다. PCR은 모래사장의 모래알을 확대하는 것과 같으며, 모래알 하나하나를 세밀하게 조사할 수 있을 뿐만 아니라 수백만 개의 동일한 복제본을 생성할 수 있기 때문에 종합적인 분석이 가능합니다.
PCR의 과정에는 면밀하게 통제된 일련의 단계가 있습니다. 먼저 표적 DNA를 분리하고 열을 가하여 이중 나선이 단일 가닥으로 분리됩니다. 그 후, 프라이머(표적 영역의 시작과 끝과 일치하도록 설계된 특정 DNA 조각)가 도입됩니다. 그 후, DNA 중합효소로 알려진 효소가 사용됩니다.
PCR 기술은 정확성, 자동화, 정밀도, 실시간 정량화, 높은 민감도로 인해 점점 더 많이 채택되고 있으며, qPCR은 다양한 입력 핵산을 제공하여 연구 응용 분야에서 실용적이고 가치 있는 기술로 자리매김하고 있습니다. 연구 응용 분야에서 실용적이고 가치 있는 기술이 되었습니다. 종양학 및 유전병 연구, 줄기세포 연구, 병원체 검출, 전염병 연구, 약리유전체학, 의약품 분석, 농업생명공학, 식물과학 연구 등 다양한 분야에서 응용되고 있습니다. 또한 법의학 분야에서도 많이 활용되고 있습니다.
알츠하이머병, 터너증후군, 파킨슨병과 같은 만성질환과 감염성 질환, 유전성 질환의 유병률 증가. 또한 선천성 심장병 환자 수가 증가하고 있으며, 정확한 진단을 위해 의료 전문가가 분자진단 도구를 사용해야 하는 상황입니다. WHO의 유럽 책임자에 따르면, 코로나 바이러스 감염 환자의 사망자 10명 중 8명은 심혈관 질환/고혈압, 당뇨병, 기타 만성 기저질환을 앓고 있는 환자였습니다고 합니다. qPCR 장비 및 소모품에 대한 수요는 SARS-CoV-2의 대유행이 주도하고 있으며, 코로나19의 발병률 증가로 인해 예방적 검사가 급증할 것으로 예상되어 시장 성장을 가속할 것으로 예측됩니다.
Bio-Rad Laboratories의 CFX Connect PCR Detection System의 가격은 약 17,995달러로, Thermo Fisher Scientific의 7900 HT qPCR 시스템은 20,000-30만 달러에 달하는 것으로 알려졌습니다. 이에 비해 Thermo Fisher Scientific의 7900 HT qPCR 시스템의 가격은 20,000-3만 달러입니다. 보다 정확한 결과와 민감도로 알려진 디지털 PCR 장비는 실시간 PCR 장비보다 높은 가격대를 형성하고 있습니다. 수동 dPCR 장비의 비용은 65,000-7만 달러로 추정되며, 자동화된 dPCR 장비의 가격은 10만 달러에 육박합니다.
또한, 시료 준비 및 PCR 공정 중 오염은 위양성 결과를 초래할 수 있으며, 이는 다양한 응용 분야, 특히 진단 환경에서 중요한 의미를 가질 수 있다는 것이 인식되고 있습니다. 오염원은 다양하며, 환경 DNA, 샘플 간 교차 오염, 이전 PCR 반응의 이월 등 다양한 오염원이 있습니다. 이러한 문제를 완화하기 위해서는 견고한 프로토콜을 시행하고, 잘 훈련된 인력을 고용하고, 지속적인 품질 관리 수단을 유지해야 하는 것으로 이해되고 있습니다. 이러한 조치에는 전용 PCR 워크스테이션 사용, 장비의 UV 멸균, 각 PCR 실행에 음성 대조군 포함 등이 포함됩니다.
Polymerase Chain Reaction PCR Market - 2026-2032
The increase in infectious disease burden, personalized medicine revolution, genomics research boom & cancer diagnostics and monitoring in the healthcare sector. Thus, the growing infectious disease burden, personalized medicine revolution, genomics research boom & cancer diagnostics, and monitoring in the healthcare sector surge the growth of market size surpassing USD 10.95 Billion in 2024 to reach the valuation of USD 17.32 Billion by 2032.
Forensic science advancements are becoming more and more popular in developing countries and small-scale industries due to DNA profiling from minuscule crime scene samples. Thus, forensic science advancements are gaining popularity in emerging countries enabling the market to grow at a CAGR of 6.50% from 2026 to 2032.
Polymerase Chain Reaction PCR Market: Definition/ Overview
The Polymerase Chain Reaction (PCR) is considered a groundbreaking technique by which millions of copies can be generated from a minuscule DNA sample. An analogy can be drawn to magnifying a single grain of sand on a beach. Through PCR, not only can that individual grain be scrutinized, but millions of identical replicas can also be produced, enabling comprehensive analysis.
A series of meticulously controlled steps is involved in the PCR process. Initially, the target DNA is isolated and subjected to heat, causing the double helix to be separated into single strands. Primers, which are specific DNA fragments designed to match the target region's beginning and end, are then introduced. Subsequently, an enzyme known as DNA polymerase is employed.
The increase in demand for rapid diagnostic tests and the growing adoption of PCR technologies are the dominant reasons for the growth of the polymerase chain reaction PCR market. PCR techniques are being increasingly adopted due to their accuracy, automation, precision, real-time quantification, and sensitivity. A wide range of input nucleic acids is offered by qPCR, making it a practical and valuable technology in research applications. Diverse applications are found in areas such as oncology & genetic disease research, stem cell research, pathogen detection, research of infectious diseases, pharmacogenomics, pharmaceutical analytics, agricultural biotechnology, and plant sciences research. It is also significantly used in forensic sciences.
The increase in the prevalence of chronic & infectious diseases and genetic disorders, such as Alzheimer's disease, Turner syndrome, & Parkinson's disease. Furthermore, the number of patients with congenital heart disease is increasing, necessitating the use of molecular diagnostic tools by medical professionals for accurate diagnoses. Cancer prevalence is expected to be increased by unhealthy dietary habits, obesity, high tobacco & alcohol consumption, and a sedentary lifestyle. According to WHO Regional Director for Europe, 8 out of 10 deaths in coronavirus-infected patients were suffered by those with cardiovascular diseases/hypertension, diabetes, and other chronic underlying conditions. The demand for qPCR equipment and consumables is being driven by the SARS-CoV-2 pandemic. A surge in preventive screenings is expected to be prompted by the increasing incidence of COVID-19, facilitating market growth.
The high QPCR device costs hinder the growth of the polymerase chain reaction PCR market. It is reported that the CFX Connect PCR Detection System by Bio-Rad Laboratories is priced at approximately USD 17,995. In comparison, Thermo Fisher Scientific's 7900 HT qPCR system is found to be priced between USD 20,000 and USD 30,000. Digital PCR instruments, which are known for more accurate results and sensitivity, are priced higher than real-time PCR instruments. The cost of a manual dPCR instrument is estimated to be between USD 65,000 and USD 70,000, while automated dPCR instruments can be priced at nearly USD 100,000.
Furthermore, it has been recognized that contamination during sample preparation or the PCR process can lead to false positive results, which can have significant implications in various applications, particularly in diagnostic settings. The sources of contamination are diverse and can include environmental DNA, cross-contamination between samples, or carryover from previous PCR reactions. It is understood that mitigating these issues requires the implementation of robust protocols, the employment of well-trained personnel, and the maintenance of ongoing quality control measures. These measures may include the use of dedicated PCR workstations, UV sterilization of equipment, and the inclusion of negative controls in each PCR run.
The consumable & reagents segment dominates in the polymerase chain reaction market. The well-surface characteristics of PCR consumables are being recognized as a critical factor in the segment's growth. It is understood that the surface properties of the wells can significantly impact the efficiency of DNA amplification. Surfaces that are optimized for DNA binding and release are being developed, which is contributing to improved PCR results. Furthermore, it has been noted that different surface treatments are being applied to enhance the compatibility of consumables with various sample types and PCR chemistries.
Material properties of PCR consumables are also being identified as a key driver of the segment's expansion. It is being reported that manufacturers are focusing on developing materials that offer superior heat conductivity and thermal stability. These properties are essential for ensuring rapid and uniform temperature changes during PCR cycles. Furthermore, materials that minimize evaporation and prevent sample loss are being increasingly adopted, which is leading to more consistent and reliable results.
The clinical diagnostic segment dominates the polymerase chain reaction market. The growth of the clinical diagnostics segment is being significantly propelled by the rapidly evolving disciplines of personalized medicine and genomics research in the healthcare sector. It is observed that PCR techniques are being increasingly relied upon for crucial activities such as gene analysis and variation detection within these fields. As advancements are made in personalized medicine and genomics, a corresponding surge in the demand for PCR applications is being witnessed in the life sciences sector. The role of PCR in routine diagnostics is being further solidified by the rising burden of infectious diseases, which is contributing to its increased adoption. While both clinical diagnostics and life sciences applications are expected to make substantial contributions to market growth, it is anticipated that clinical diagnostics may hold a slight advantage in the near term due to its established position in routine testing protocols. However, it is projected that the life sciences segment has the potential to emerge as the dominant application in the long run, driven by its association with cutting-edge research and progress in personalized care approaches.
North America is the dominating region in the polymerase chain reaction (PCR) market. The strong market presence in North America is attributed to well-developed healthcare systems, which are characterized by high levels of research funding and access to advanced technologies. A strong understanding of PCR applications is often observed among the general public and healthcare professionals in North America, which is leading to greater demand for diagnostic tests and research tools. Strict guidelines for diagnostic tests and medical devices are enforced by regulatory bodies in North America. This emphasis on quality ensures accuracy and reliability, thereby driving market growth through the adoption of advanced PCR instruments and assays. As a result of these factors, North America's position as the dominant force in the PCR market is being solidified.
Europe is the fastest-growing region in the polymerase chain reaction (PCR) market during the forecast period characterized by a mature market landscape where innovation is highly prioritized. A significant number of leading research institutions are housed in Europe, where heavy reliance on PCR for various applications in life sciences is observed. The advancement of PCR technology and the fostering of a dynamic market environment are being fueled by government support for research and development activities. A growing emphasis on personalized medicine is being witnessed across Europe, by which a demand for sophisticated PCR tools used in genetic analysis and tailored healthcare approaches is being created. These factors are collectively contributing to Europe's rapid growth in the PCR market, positioning it as a region where cutting-edge developments and increasing adoption of PCR technologies are being consistently observed.
The Polymerase Chain Reaction PCR Market continues to change and evolve with innovations and also new technologies. There is a continuous promotion of new materials and the improvement of sensors. Cloud-based delivery by companies needs to meet new industry requirements and demands. The market share for polymerase chain reaction PCR is an intense and consistently evolving field where new and old players are still fighting for occupation.
Some of the key players operating in the polymerase chain reaction PCR market include:
Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Merck KGaA, Agilent Technologies, Inc.
Danaher Corporation
Bio-Rad Laboratories Inc.
QIAGEN N.V.
Abbott Laboratories
Takara Bio Inc.
Becton
Dickinson and Company
Polymerase Chain Reaction (PCR) Market Latest Developments
In October 2024, Abbott Laboratories announced that they got clearance for their Alinity mPCR System, a real-time PCR platform for clinical laboratories. This user-friendly, automated system aimed to expand PCR technology access for various diagnostic applications.
In May 2024, Thermo Fisher Scientific announced the launch of the Applied Biosystems TaqMan MiniChip PCR System, a miniaturized platform for point-of-care settings. This development addressed the market's growing interest in portable PCR solutions for rapid diagnostics in resource-limited environments.